Coremans G, Margaritis V, Snoeck R, Wyndaele J, De Clercq E, Geboes K
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium.
Dis Colon Rectum. 2003 Aug;46(8):1103-8; discussion 1108-9. doi: 10.1007/s10350-004-7287-5.
Human papilloma virus infections of the anogenital region are very common and cause condylomata acuminata; cervical, penile, vulvar, or perianal intraepithelial neoplasia; and more rarely, invasive cancer. The currently available therapies often result in painful, extensive, slow-healing ulcerations and frequent early relapses. This study was aimed at determining the efficacy of topical application of the antiviral agent cidofovir at 1 percent.
Twenty patients treated with coagulations were compared with 27 patients treated with cidofovir. Lesions refractory to cidofovir were cleared up with additional coagulations. The number of patients previously treated for condylomata did not differ between the two groups. Significantly more patients treated with cidofovir, however, had an impaired immune status (37 percent) compared with the patients treated with coagulations (5 percent).
Cidofovir alone cured the lesions in 32 percent of the patients and induced partial regression in 60 percent. However, in smokers, complete resolution of the condylomata occurred only in 16.6 percent compared with 66 percent of nonsmokers (P = 0.03). The number of coagulation sessions was much lower (P < 0.0005) in the cidofovir treated group (1 +/- 0.8 vs. 2.9 +/- 2). Furthermore, the relapse rate was significantly lower in the cidofovir group (3.7 vs. 55). All recurrences in the electrocoagulation group occurred within four months of confirmed lesion clearance. Topical applications of cidofovir 1 percent were well tolerated. Thirty-three percent of the patients reported only mild pain caused by erosive dermatitis. In contrast, coagulations caused painful ulcerations that necessitated the use of analgesics in all patients treated this way.
Topical applications of cidofovir, an antiviral compound with activity against human papilloma virus, is effective in the majority of patients with perianal condylomata and is a valuable adjuvant to surgical treatment of these lesions.
肛门生殖器区域的人乳头瘤病毒感染非常常见,可引起尖锐湿疣、宫颈、阴茎、外阴或肛周上皮内瘤变,更罕见的是侵袭性癌症。目前可用的治疗方法常常导致疼痛、广泛、愈合缓慢的溃疡以及频繁的早期复发。本研究旨在确定局部应用1%的抗病毒药物西多福韦的疗效。
将20例接受凝固治疗的患者与27例接受西多福韦治疗的患者进行比较。对西多福韦难治的病变通过额外的凝固治疗清除。两组中先前接受过尖锐湿疣治疗的患者数量无差异。然而,与接受凝固治疗的患者(5%)相比,接受西多福韦治疗的患者免疫状态受损的比例显著更高(37%)。
单独使用西多福韦使32%的患者病变治愈,60%的患者病变部分消退。然而,在吸烟者中,尖锐湿疣完全消退的比例仅为16.6%,而非吸烟者为66%(P = 0.03)。西多福韦治疗组的凝固治疗次数明显更少(P < 0.0005)(1 ± 0.8次 vs. 2.9 ± 2次)。此外,西多福韦组的复发率显著更低(3.7% vs. 55%)。电凝组的所有复发均发生在病变确认清除后的四个月内。局部应用1%的西多福韦耐受性良好。33%的患者仅报告有糜烂性皮炎引起的轻度疼痛。相比之下,凝固治疗会导致疼痛性溃疡,所有接受这种治疗的患者都需要使用镇痛药。
局部应用具有抗人乳头瘤病毒活性的抗病毒化合物西多福韦,对大多数肛周尖锐湿疣患者有效,是这些病变手术治疗的一种有价值的辅助治疗方法。